Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Faster Complete Abortion With Reduced Interval Between Mifepristone and Misoprostol

SAN FRANCISCO — A reduced time from mifepristone to misoprostol during the second trimester significantly reduced the time from mifepristone to complete abortion, a prospective

May 22, 2024

J&J’s Ottava robot arriving too late to threaten Intuitive: analysts

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Analysts have praised the features

November 9, 2023

Catalent, which is being acquired by Novo, reports 10% drop in second-quarter revenue

Four days after Novo Holdings announced plans to buy Catalent for $16.5 billion, the CDMO revealed its financial health in its fiscal second quarter. Catalent

February 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.